Hyponatremia in ICU.

Background: Hyponatremia is defined as serum sodium level <135 meq/L. It is the most common electrolyte abnormality seen in hospital admissions worldwide. The proportion is even higher in the ICU setting. A wide variety of factors influence the outcome of the hyponatremic patient. Present study is designed to approach to analyse etiology, clinical features, co-morbid factors, severity of hyponatremia, rate of correction, and impact of treatment on outcome of these diverse group of patients in ICU. Aims: 1) To find proportion of patients presenting with hyponatremia and requiring medical ICU admission in a tertiary care set up. 2) To study the etiology and clinical features of hyponatremia in patients requiring ICU admission. 3) To compare and study the effect of various factors on the outcome of hyponatremic patients in the ICU. Methods: This study was a cross-sectional observational study in tertiary care hospital. All indoor general medicine ward admissions over a period of 18 months were screened for the presence of hyponatremia and patients requiring Medical ICU care and satisfying inclusion criteria were studied. Serial serum electrolytes and urine sodium were tested for all patients in the ICU satisfying the inclusion criteria. Type of fluid given and daily correction of serum sodium of all patients were noted. Outcome was measured in terms of mortality, duration of stay in ICU, number of days required for sodium correction and complications of treatment if any. Patients were followed up till hospital discharge or death.. Results: In this study, 5.2% of total admissions had hyponatremia. Among the ICU admissions, the different symptoms attributed to hyponatremia included nausea (69.3%), malaise (80%), drowsiness (61.3%), confusion (41.3%), lethargy (24%), frequent falls (1.3%), convulsions (2.7%), altered sensorium (41.3%) and delirium (9.3%). SIADH was the most common cause of hyponatremia in these patients (32%). Serum sodium levels of patients on admission ranged from 82 - 133 meq/L, with average serum sodium being 124meq/L. Overall mortality among the hyponatremic ICU admissions was 26/75, 34.6%, which was higher than the total ICU mortality of 26% in same duration (p = 0.1). There was a significant increase in duration of stay in ICU in patients with various co-morbidities (p=0.003). There was a significant association between Glasgow Coma Scale (GCS) and serum sodium levels, (p = 0.002). Blood pressure and hydration status did not significantly influence outcome. Lower serum sodium on admission was associated with a lower survival (p= 0.041). Sodium correction of < 5 m eq/day was associated with an increased mortality(p = 0.04), whereas sodium correction of > 10 m eq/day was not associated with increased mortality, but an increased risk of EPM, which was seen in one patient. Conclusion: Most common cause of hyponatremia in ICU patients is SIADH. Longer duration of stay is seen in the presence of different co-morbidities. A lower GCS and a lower serum sodium on admission is associated with lower survival. Type of fluid used for hyponatremia correction did not influence the outcome. Under correction of hyponatremia in first 24 hours or inadequate correction was associated with a poorer outcome. Overcorrection was not associated with any survival benefit, but was associated with risk of EPM.

Metronidazole-Induced Encephalopathy in Chronic Diarrhoea.

Metronidazole-induced encephalopathy (MIE) is a rare cause of drug-induced toxic encephalopathy. We report the clinical and neuroimaging findings of a patient with chronic diarrhoea who developed metronidazole-induced encephalopathy. After the drug was discontinued there was complete reversal of the condition.

Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study.

PURPOSE: Ulinastatin, a serine protease inhibitor, inhibits several pro-inflammatory proteases and decreases inflammatory cytokine levels and mortality in experimental sepsis. We studied the effect of ulinastatin on 28-day all-cause mortality in a double-blind trial in patients with severe sepsis in seven Indian hospitals. METHODS: Patients with sepsis were randomized within 48 h of onset of one or more organ failures to receive intravenous administration of ulinastatin (200,000 IU) or placebo 12 hourly for 5 days. RESULTS: Of 122 randomized subjects, 114 completed the study (55 receiving ulinastatin, 59 receiving placebo). At baseline, the mean APACHE II score was 13.4 (SD = 4.4), 48 (42 %) patients were receiving mechanical ventilation, 58 (51 %) were on vasopressors, and 35 % had multiple organ failure. In the modified intention-to-treat analysis (patients receiving six or more doses of study drugs), 28-day all-cause mortality was 7.3 % with ulinastatin (4 deaths) versus 20.3 % (12 deaths) with placebo (p = 0.045). On multivariate analysis too, treatment with ulinastatin (odds ratio 0.26, 95 % CI 0.07-0.95; p = 0.042) independently decreased 28-day all-cause mortality. However, the mortality difference did not reach statistical significance in the intention-to-treat analysis [10.2 % (6/59 deaths) with ulinastatin versus 20.6 % (13/63 deaths) in the placebo group; p = 0.11]. The ulinastatin group had lower incidence of new-onset organ failure (10 vs. 26 patients, p = 0.003), more ventilator-free days (mean ± SD 19.4 ± 10.6 days vs. 10.2 ± 12.5 days, p = 0.019), and shorter hospital stay (11.8 ± 7.1 days vs. 24.2 ± 7.2 days, p < 0.001). CONCLUSIONS: In this pilot study, intravenous administration of ulinastatin reduced mortality in patients with severe sepsis in the modified intention-to-treat analysis, but not in the intention-to-treat analysis.

Bilateral breast in brothers - abreast.

Gynecomastia is a common occurrence in pubertal age group, and is physiological in up to 65 percent of cases. When occurs in the family it should be investigated in order not to miss on a treatable etiology. Two brothers within the same family, presenting with bilateral gynecomastia of different causes and requiring different treatment are presented.

An unusual cause of flash pulmonary oedema.

We report a case of young woman who presented with acute cardiogenic pulmonary oedema and respiratory failure. She underwent emergent endotracheal intubation and was transferred to the intensive care unit. She responded to intravenous diuretics and positive pressure ventilation. Subsequent workup revealed that she had Graves' disease and was in thyrotoxic crisis. Therapy with propranolol and propylthiouracil was instituted to which she showed remarkable improvement.

Acute aortic syndrome--penetrating atherosclerotic ulcer with contained rupture managed by endovascular stent-grafting.

We present the case of a hypertensive male who came with acute onset of severe backache and hypotension. Emergency imaging revealed a penetrating atherosclerotic ulcer of descending thoracic aorta with contained rupture and bilateral hemothorax. Initially stabilised with medical management, this patient went on to undergo endovascular stent-grafting. The sequence of clinical events of this uncommon entity and the relatively novel interventional modality are reviewed.

Suprasellar tuberculoma presenting as panhypopituitarism.

Suprasellar tuberculomas are exceptionally rare. We present the case of a middle aged male who presented with generalised apathy and meningism of two weeks duration. Neuroimaging was suggestive of tuberculomas in suprasellar cistern, while endocrinological investigation showed panhypopituitarism manifesting as pituitary hypothyroidism, hypocortisolism, and hyperprolactinemia. Cerebrospinal fluid examination showed lymphocytic reaction with raised proteins. A diagnosis of suprasellar tuberculoma with panhypopituitarism was made. The patient was started on antituberculous treatment and hormone replacement which led to remarkable improvement in condition of patient and resolution of tuberculous granuloma in follow up imaging.